{"id":10092,"date":"2012-06-25T17:11:40","date_gmt":"2012-06-25T21:11:40","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=10092"},"modified":"2012-06-25T17:11:40","modified_gmt":"2012-06-25T21:11:40","slug":"merck-serono-compugen-to-form-toxicity-biomarkers-start-up","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=10092","title":{"rendered":"Merck Serono, Compugen to Form Toxicity Biomarkers Start-Up"},"content":{"rendered":"<figure id=\"attachment_4593\" aria-describedby=\"caption-attachment-4593\" style=\"width: 267px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/06\/DNA_GenomeGov.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-4593\" title=\"DNA_GenomeGov\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/06\/DNA_GenomeGov.jpg\" alt=\"DNA strand (Genome.gov)\" width=\"267\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/06\/DNA_GenomeGov.jpg 267w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/06\/DNA_GenomeGov-150x112.jpg 150w\" sizes=\"auto, (max-width: 267px) 100vw, 267px\" \/><\/a><figcaption id=\"caption-attachment-4593\" class=\"wp-caption-text\">(Genome.gov)<\/figcaption><\/figure>\n<p><a href=\"http:\/\/www.merckserono.com\/corp.merckserono_2011\/en\/images\/20120625_en_tcm1494_96507.pdf\">Merck Serono<\/a>, a division of the global pharmaceutical company Merck in Geneva, Switzerland and the drug discovery company <a href=\"http:\/\/cgen.com\/Default.aspx\">Compugen<\/a> in Tel Aviv, Israel have agreed to form Neviah Genomics, a new enterprise to develop biomarkers for the prediction of drug-induced toxicity. While some financial arrangements were revealed, the total value of the deal was not disclosed.<\/p>\n<p>Neviah Genomics, say the companies, will focus on the growing need for biomarker-related methods of predicting toxicity profiles of drug candidates at an early stage of development. These methods can help drug developers minimize attrition and mitigate the risk of late-stage drug failure.<\/p>\n<p>Neviah Genomics is expected to operate in a bioincubator program out of Merck Serono&#8217;s Israeli R&amp;D center that opened last month. The new enterprise \u00a0is the first company in the bioincubator program.<\/p>\n<p>Merck Serono, Merck&#8217;s biopharmaceutical division, and Compugen collaborated earlier on biomarker signatures for drug induced toxicity. In the new collaboration, Merck Serono Ventures will provide the initial funding for Neviah Genomics.<\/p>\n<p>&#8220;Neviah Genomics is a perfect illustration of our goals behind the establishment of the Israel Biotech Incubator,&#8221; says Susan Herbert, executive vice president at Merck Serono, &#8220;to leverage Israeli science and know-how and get access to novel products and technologies for the benefit of Merck Serono\u2019s core therapeutic areas.&#8221;<\/p>\n<p>Neviah Genomics will receive access to Compugen&#8217;s computational discovery platforms to develop genomics-based diagnostic tests for toxicity. Compugen will receive an equity stake in Neviah Genomics and a right to royalties from potential future sales.<\/p>\n<p>Read more:<\/p>\n<ul>\n<li><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=3806\" rel=\"prev\">Merck to Offer Biotech Funding, Incubator in Israel<\/a><\/li>\n<li><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=2613\">Biotech Lands $5 Million Investment Deal<\/a><\/li>\n<\/ul>\n<p style=\"text-align: center;\">* \u00a0 \u00a0 * \u00a0 \u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Serono, a division of the global pharmaceutical company Merck in Geneva, Switzerland and the drug discovery company Compugen in Tel Aviv, Israel have agreed to form Neviah Genomics, a new enterprise to develop biomarkers for the prediction of drug-induced toxicity. While some financial arrangements were revealed, the total value of the deal was not [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,16],"tags":[31,21,74,23,45,24,114,64,77,19],"class_list":["post-10092","post","type-post","status-publish","format-standard","hentry","category-finance","category-ventures","tag-biomedical","tag-biotech","tag-entrepreneurs","tag-equity","tag-europe","tag-investment","tag-israel","tag-life-sciences","tag-medical-device","tag-venture-capital"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/10092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10092"}],"version-history":[{"count":4,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/10092\/revisions"}],"predecessor-version":[{"id":10096,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/10092\/revisions\/10096"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}